Lipid Profile as Predictor of Adverse Maternal and Neonatal Outcomes: A Pilot Study
Study Details
Study Description
Brief Summary
The purpose of this study is to ascertain lipid profiles during pregnancy, specifically during the 24-28 week gestation and again near term at 36 weeks gestation. The research team are investigating whether lipid profiles can predict adverse maternal and neonatal outcomes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
The purpose of this research is to investigate whether lipids profiles during pregnancy impact LGA and other adverse outcomes in pregnancy. Participants will have blood drawn twice; the first blood work is a fasting blood draw (separate blood draw) on the same day but preceding the standard glucose test. The second blood draw is drawn at the time of routine clinical care (third trimester blood work).
Patients will be approached at the time of the anatomy ultrasound for participation. If they consent to participate they will have a FASTING lipid panel drawn at the time of their 24-28w GCT and again at the time of their 36w third trimester labs. Patients will receive a reminder call prior to scheduled 24-28 week appointment for fasting instructions.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| LGA neonates Researchers will compare lipid levels in large for gestational age (LGA) and non-LGA neonates. |
|
| non-LGA neonates Researchers will compare lipid levels in large for gestational age (LGA) and non-LGA neonates. |
Outcome Measures
Primary Outcome Measures
- Neonatal birthweight [at birth, day 1]
Neonatal birthweight will be classified as large for gestational age (LGA) or non-LGA
Secondary Outcome Measures
- Number of participants with preeclampsia [at birth, day 1]
- Number of participants with gestational diabetes [at birth, day 1]
- Total Cholesterol [at 24-28 weeks gestation]
Total Cholesterol obtained while fasting at 24-28 weeks gestation. Different blood tests can be done to measure each type of cholesterol. Total cholesterol level measures all types of cholesterol in the blood.
- Total Cholesterol [at 36 weeks gestation]
Total Cholesterol obtained while fasting at 36 weeks gestation. Different blood tests can be done to measure each type of cholesterol. Total cholesterol level measures all types of cholesterol in the blood.
- High-Density Lipoprotein Cholesterol (HDL) [at 24-28 weeks gestation]
High-Density Lipoprotein Cholesterol (HDL) obtained while fasting at 24-28 weeks. HDL helps keep arteries open and reduces the risk for heart attack. High levels of HDL may be nearly as protective for the heart as low levels of LDL
- High-Density Lipoprotein Cholesterol (HDL) [at 36 weeks gestation]
High-Density Lipoprotein Cholesterol (HDL) obtained while fasting at 36 weeks. HDL helps keep arteries open and reduces the risk for heart attack. High levels of HDL may be nearly as protective for the heart as low levels of LDL
- Triglycerides [at 24-28 weeks gestation]
Triglycerides obtained while fasting at 24-28 weeks gestation. Triglycerides interact with HDL cholesterol in such a way that HDL levels fall as triglyceride levels rise. High triglyceride levels are also associated with the inflammatory response -- the harmful effect of an overactive immune system that can cause considerable damage to cells and tissues, including the arteries.
- Triglycerides [at 36 weeks gestation]
Triglycerides obtained while fasting at 36 weeks gestation. Triglycerides interact with HDL cholesterol in such a way that HDL levels fall as triglyceride levels rise. High triglyceride levels are also associated with the inflammatory response -- the harmful effect of an overactive immune system that can cause considerable damage to cells and tissues, including the arteries.
- Low-Density Lipoprotein Cholesterol (LDL) [at 24-26 weeks gestation]
Low-Density Lipoprotein Cholesterol (LDL) obtained while fasting at 24-28 weeks gestation. Low-density lipoprotein (LDL) transports about 75% of the blood's cholesterol to the body's cells. Heart disease is least likely to occur among people with the lowest LDL levels. Lowering LDL is the primary goal of cholesterol drug and lifestyle therapy.
- Low-Density Lipoprotein Cholesterol (LDL) [at 36 weeks gestation]
Low-Density Lipoprotein Cholesterol (LDL) obtained while fasting at 36 weeks gestation. Low-density lipoprotein (LDL) transports about 75% of the blood's cholesterol to the body's cells. Heart disease is least likely to occur among people with the lowest LDL levels. Lowering LDL is the primary goal of cholesterol drug and lifestyle therapy.
- Very-low-density Lipoprotein Cholesterol (VLDL) [at 24-26 weeks gestation]
Very-low-density Lipoprotein Cholesterol (VLDL) obtained while fasting at 24-28 weeks gestation. VLDL is one of the three main types of lipoproteins. Lipoproteins are made up of cholesterol, triglycerides, and proteins. They move cholesterol, triglycerides, and other lipids (fats) around the body.
- Very-low-density Lipoprotein Cholesterol (VLDL) [at 36 weeks gestation]
Very-low-density Lipoprotein Cholesterol (VLDL) obtained while fasting at 36 weeks gestation. VLDL is one of the three main types of lipoproteins. Lipoproteins are made up of cholesterol, triglycerides, and proteins. They move cholesterol, triglycerides, and other lipids (fats) around the body.
- Total Cholesterol/HDL Ratio [at 24-26 weeks gestation]
Total Cholesterol/HDL Ratio obtained while fasting at 24-28 weeks gestation. The total cholesterol /HDL ratio is the proportion of one type of cholesterol to all the other cholesterol in the blood. Total cholesterol includes three substances HDL, LDL, and VLDL. Higher ratios indicate greater risk of heart coronary heart disease.
- Total Cholesterol/HDL Ratio [at 36 weeks gestation]
Total Cholesterol/HDL Ratio obtained while fasting at 36 weeks gestation. The total cholesterol /HDL ratio is the proportion of one type of cholesterol to all the other cholesterol in the blood. Total cholesterol includes three substances HDL, LDL, and VLDL. Higher ratios indicate greater risk of heart coronary heart disease.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Singleton pregnancy
-
Ages 18-45
-
Presentation to prenatal care by the 2nd trimester
-
Prenatal care at Mount Sinai Hospital
-
Anticipated delivery at Mount Sinai Hospital
Exclusion Criteria:
-
Multiple gestations
-
Preexisting hyperlipidemia
-
Preexisting diabetes
-
Delayed presentation to prenatal care after the 2nd trimester 5. Prenatal care or delivery outside of Mount Sinai Health System
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mount Sinai OBGYN Faculty Practice Associates | New York | New York | United States | 10029 |
Sponsors and Collaborators
- Icahn School of Medicine at Mount Sinai
Investigators
- Principal Investigator: Luciana Vieira, MD, MS, Icahn School of Medicine at Mount Sinai
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STUDY-21-01936-MOD002